CytomX Therapeutics (NASDAQ: CTMX)
$2.12
(11.0%)
$0.21
Price as of August 18, 2025, 4:00 p.m. ET
CytomX Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CytomX Therapeutics Company Info
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
News & Analysis
Valuation
Earnings Transcripts
CytomX Therapeutics (CTMX) Q2 2022 Earnings Call Transcript
CTMX earnings call for the period ending June 30, 2022.
Motley Fool Transcribing | Aug 5, 2022
CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript
CTMX earnings call for the period ending March 31, 2022.
Motley Fool Transcribing | May 6, 2022
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
CTMX earnings call for the period ending December 31, 2021.
Motley Fool Transcribing | Mar 2, 2022
CytomX Therapeutics, inc (CTMX) Q3 2021 Earnings Call Transcript
CTMX earnings call for the period ending September 30, 2021.
Motley Fool Transcribers | Nov 5, 2021
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.